MA71622A - Domaines de liaison à l'antigène cd98hc et leurs utilisations - Google Patents

Domaines de liaison à l'antigène cd98hc et leurs utilisations

Info

Publication number
MA71622A
MA71622A MA71622A MA71622A MA71622A MA 71622 A MA71622 A MA 71622A MA 71622 A MA71622 A MA 71622A MA 71622 A MA71622 A MA 71622A MA 71622 A MA71622 A MA 71622A
Authority
MA
Morocco
Prior art keywords
cd98hc
antigen
binding domains
domains
binding
Prior art date
Application number
MA71622A
Other languages
English (en)
Inventor
Eric Brown
Rajkumar Ganesan
Angie Grace YEE
Lu Shan
Alexander Gregory GULEVICH
Hamid SALIMI
Margaret L. TANG
Tarangsri Nivitchanyong
Sarah A. JAHN
Thunga BIENLY
Raymond Ka-Hang TONG
Alexander Hyun-min YANG
Original Assignee
Alector Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alector Llc filed Critical Alector Llc
Publication of MA71622A publication Critical patent/MA71622A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA71622A 2022-07-29 2023-07-28 Domaines de liaison à l'antigène cd98hc et leurs utilisations MA71622A (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263369885P 2022-07-29 2022-07-29
US202363489675P 2023-03-10 2023-03-10
US202363495514P 2023-04-11 2023-04-11
EP23758167.3A EP4561614A1 (fr) 2022-07-29 2023-07-28 Domaines de liaison à l'antigène cd98hc et leurs utilisations
PCT/US2023/071238 WO2024026471A1 (fr) 2022-07-29 2023-07-28 Domaines de liaison à l'antigène cd98hc et leurs utilisations

Publications (1)

Publication Number Publication Date
MA71622A true MA71622A (fr) 2025-05-30

Family

ID=87760570

Family Applications (1)

Application Number Title Priority Date Filing Date
MA71622A MA71622A (fr) 2022-07-29 2023-07-28 Domaines de liaison à l'antigène cd98hc et leurs utilisations

Country Status (9)

Country Link
US (1) US20250270341A1 (fr)
EP (1) EP4561614A1 (fr)
JP (1) JP2025528751A (fr)
CN (1) CN119584983A (fr)
AU (1) AU2023316021A1 (fr)
CA (1) CA3261511A1 (fr)
MA (1) MA71622A (fr)
MX (1) MX2025000569A (fr)
WO (1) WO2024026471A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025166040A1 (fr) 2024-01-31 2025-08-07 Alector Llc Protéines de liaison multi-spécifiques qui se lient à gpnmb et à une cible de barrière hémato-encéphalique et procédés pour les utiliser
WO2025166045A1 (fr) 2024-01-31 2025-08-07 Alector Llc ENZYMES DE β-GLUCOCÉRÉBROSIDASE, PROTÉINES DE FUSION ET COMPLEXES LES COMPRENANT, ET LEURS PROCÉDÉS D'UTILISATION
WO2025166042A1 (fr) * 2024-01-31 2025-08-07 Alector Llc Domaines de liaison à l'antigène cd98hc et leurs utilisations
WO2025247301A1 (fr) * 2024-05-30 2025-12-04 Sironax Switzerland Gmbh Nouveaux anticorps spécifiques d'une chaîne lourde cd98 et leurs procédés d'utilisation
CN120842376A (zh) * 2025-07-28 2025-10-28 郑州伊美诺生物技术有限公司 广谱特异性抗体及其应用

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB2183662B (en) 1985-04-01 1989-01-25 Celltech Ltd Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP0590058B1 (fr) 1991-06-14 2003-11-26 Genentech, Inc. ANTICORP HUMANISE specifique pour heregulin
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993011794A1 (fr) 1991-12-13 1993-06-24 Xoma Corporation Procedes et matieres de preparation de domaines variables d'anticorps modifies et leurs utilisations therapeutiques
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
CA2372813A1 (fr) 1992-02-06 1993-08-19 L.L. Houston Proteine fixatrice biosynthetique pour marqueur du cancer
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US7951917B1 (en) 1997-05-02 2011-05-31 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
EP0979281B1 (fr) 1997-05-02 2005-07-20 Genentech, Inc. Procede de preparation d'anticorps multispecifiques presentant des composants heteromultimeres
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
WO1999029888A1 (fr) 1997-12-05 1999-06-17 The Scripps Research Institute Humanisation d'anticorps murins
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
AU2002368077B2 (en) 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
WO2006028936A2 (fr) 2004-09-02 2006-03-16 Genentech, Inc. Molecules heteromultimeriques
EP2016101A2 (fr) 2006-05-09 2009-01-21 Genentech, Inc. Polypeptides de liaison à squelettes optimisés
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
EP3663318A1 (fr) 2008-01-07 2020-06-10 Amgen Inc. Procédé de fabrication de molécules hétérodimères fc d'anticorps utilisant les effets de conduite électrostatique
WO2011143545A1 (fr) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Protéines hétérodimériques et leurs procédés de production et de purification
LT2627672T (lt) 2010-10-11 2018-12-10 Biogen International Neuroscience Gmbh Žmogaus antikūnai prieš tau baltymą
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
US20150239991A1 (en) 2012-09-25 2015-08-27 Glenmark Pharmaceuticals S.A. Purification of hetero-dimeric immunoglobulins
CA2889951C (fr) 2012-11-02 2023-04-18 Zymeworks Inc. Structures cristallines de domaines fc heterodimeres
EA032681B1 (ru) 2012-11-27 2019-07-31 Аджоу Юниверсити Индастри-Академик Кооперейшн Фаундейшн ГЕТЕРОДИМЕР Fc ИММУНОГЛОБУЛИНА, СОДЕРЖАЩИЙ ВАРИАНТ ДОМЕНА CH3 ДЛЯ ОБРАЗОВАНИЯ АНТИТЕЛА ИЛИ ГИБРИДНОГО БЕЛКА С ГЕТЕРОМЕРНЫМ Fc С ВЫСОКОЙ ЭФФЕКТИВНОСТЬЮ, СПОСОБ ДЛЯ ЕГО ПОЛУЧЕНИЯ И ИСПОЛЬЗОВАНИЯ
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
SG11201509566RA (en) 2013-05-20 2015-12-30 Genentech Inc Anti-transferrin receptor antibodies and methods of use
TWI599358B (zh) 2014-09-16 2017-09-21 美國禮來大藥廠 組合療法
ES2935274T3 (es) 2014-12-05 2023-03-03 Merck Patent Gmbh Anticuerpo con intercambio de dominios
SG11201703750XA (en) * 2014-12-10 2017-06-29 Genentech Inc Blood brain barrier receptor antibodies and methods of use
WO2018027025A1 (fr) 2016-08-03 2018-02-08 Oncomed Pharmaceuticals, Inc. Agent liant cd40 et utilisations associées
RU2019114679A (ru) 2016-11-15 2020-12-17 Х. Лундбекк А/С Средства, пути применения и способы лечения синуклеопатии
WO2019246288A1 (fr) 2018-06-22 2019-12-26 Ossianix, Inc. Vnars anti-cd98hc pour traverser la barrière hémato-encéphalique et des bibliothèques vcubitales de type iv
KR20220166304A (ko) * 2020-04-08 2022-12-16 앨리어다 테라퓨틱스, 인코포레이티드 항-cd98 항체 및 이의 용도

Also Published As

Publication number Publication date
WO2024026471A1 (fr) 2024-02-01
US20250270341A1 (en) 2025-08-28
CN119584983A (zh) 2025-03-07
EP4561614A1 (fr) 2025-06-04
JP2025528751A (ja) 2025-09-02
MX2025000569A (es) 2025-02-10
WO2024026471A9 (fr) 2024-11-07
CA3261511A1 (fr) 2024-02-01
AU2023316021A1 (en) 2025-03-06

Similar Documents

Publication Publication Date Title
MA71630A (fr) Domaines de liaison à l'antigène du récepteur de la transferrine et leurs utilisations
MA71559A (fr) Molécules de liaison à l'antigène anti-steap1 et leurs utilisations
EP4441098A4 (fr) Unité de liaison à l'antigène ccr8 et ses utilisations
EP4132969A4 (fr) Molécules de liaison à l'antigène anti-mésothéline et leurs utilisations
EP4188951A4 (fr) Molécules de liaison à un coronavirus multimériques et leurs utilisations
EP3863605A4 (fr) Vecteurs aav1 et leurs utilisations pour le traitement d'indications otiques
EP4126956A4 (fr) Molécules multispécifiques de liaison à l'antigène ciblant la claudine 6 et leurs utilisations
EP4097223A4 (fr) Agents de liaison à strad et leurs utilisations
EP4236990A4 (fr) Variants de l'interleukine-18 et leurs procédés d'utilisation
EP4330414A4 (fr) Capsides aav et leurs utilisations
EP4429672A4 (fr) Psilocybine et o-acétylpsilocine, leurs sels et formes à l'état solide
EP4200335A4 (fr) Compositions d'anticorps anti-cd5 et leurs utilisations
EP4352046A4 (fr) Composés d'isoindolinone et leurs utilisations
EP4225303A4 (fr) Agents dégradeurs de stat et leurs utilisations
EP4132974A4 (fr) Anticorps anti-cd98 et leurs utilisations
EP4257617A4 (fr) Protéine de liaison à l'antigène ciblant cd70 et son utilisation
EP3837277A4 (fr) Virus de la maladie de newcastle recombinés et leurs utilisations pour la prévention d'une maladie à rsv ou d'une maladie à métapneumovirus humain
EP4294299A4 (fr) Systèmes et méthodes de traitement d'une articulation sacro-iliaque
EP4353746A4 (fr) Anticorps humanisé anti-pd-1 ou fragment de liaison à l'antigène de celui-ci et utilisation associée
CA3256431A1 (fr) Molécules d'anticorps contre april et leurs utilisations
EP4374093A4 (fr) Systèmes de pignons segmentés et leurs procédés d'installation
EP4185303A4 (fr) Transactivateurs de domaine de liaison à l'adn et leurs utilisations
EP4240490A4 (fr) Protéines de liaison reconnaissant l'antigène ha-1 et leurs utilisations
EP4384543A4 (fr) Protéines de liaison à l'antigène et leurs utilisations
EP4642805A4 (fr) Anticorps anti-cd79b et leurs utilisations